

CURRICULUM VITAE



PERSONAL INFORMATION

Name Melania Carlisi
Address [REDACTED]
Work-Address Hematology Unit, AOUP "P. Giaccone", Via del Vespro 129, 90127 Palermo (Italy)
Telefono [REDACTED]
Fax [REDACTED]
E-mail melaniacarlisi@yahoo.it

Nationality Italy
Date of birth (mm/dd/YYYY) [REDACTED]

WORKING EXPERIENCE

- Date (da – a) August 01, 2017- Current
- Name and address of the employer Hematology Unit, AOUP "P. Giaccone" Palermo , via del Vespro 129, 90127 Palermo
- Tipo di azienda o settore AOUP "P. Giaccone" of Palermo
- Position held Medical Doctor
- Main activities and responsibilities Diagnosis and treatment of patients with onco-hematological pathologies, with particular reference to plasma cell dyscrasias

EDUCATION AND TRAINING

- Date (da – a) October, 2016 – December, 2019
- Name and type of education or training institution University of Palermo
- Main subjects/professional skills covered by the study Doctorate Course in Experimental Surgery and Oncology – University of Palermo
- Qualification awarded PhD

- Date (da – a) June, 2011 – July, 2016
- Name and type of education or training institution Oxford School of English – Oxford (UK)
- Main subjects/professional skills covered by the study English course
- Qualification awarded [REDACTED]

- Date (da – a) October, 2016
- Name and type of education or training institution Hematology Unit, AOUP "P. Giaccone" Palermo, University of Palermo

- Main subjects/professional skills covered by the study
 - Qualification awarded
 - Date (da – a)
 - Name and type of education or training institution
 - Main subjects/professional skills covered by the study
 - Qualification awarded
 - Date (da – a)
 - Name and type of education or training institution
 - Main subjects/professional skills covered by the study
 - Qualification awarded
 - Date (da – a)
 - Name and type of education or training institution
 - Main subjects/professional skills covered by the study
 - Qualifica conseguita
 - Date (da – a)
 - Name and type of education or training institution
 - Main subjects/professional skills covered by the study
 - Qualification awarded
 - Date (da – a)
 - Name and type of education or training institution
 - Main subjects/professional skills covered by the study
 - Qualification awarded
- Awarded of the "AICE Youth Project" award for the clinical management of patients with Congenital Hemorrhagic Diseases (MEC)
- June, 2011 – July, 2016
Hematology Unit, AOUP "P. Giaccone" Palermo, University of Palermo
- Acute and chronic onco-hematological disorders, thrombosis and hemostasis;
- Hematologist
Mark: 70/70 cum laude.
- January 09, 2016 – April 14, 2016
Division of Medical Oncology and Immune-Related Tumors, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy
- Training internship aimed at acquiring the main notions of clinical and therapeutic management relating to lymphoproliferative disorders
- March 01-31, 2015
Hematology Unit Policlinico "A. Gemelli", Università Cattolica del Sacro Cuore, Roma
- Training stage aimed at acquiring the main notions of morphological and flow cytometric diagnostics of hematological diseases
- September, 2010 – June, 2011
Hematology Unit, AOUP "P. Giaccone" Palermo, University of Palermo
- Post-graduate internship with specific participation in the clinical management of lymphoproliferative disorders
- October, 2004 – July, 2010
University of Palermo, Medical School
- Medical degree
- Medical Doctor
Mark: 110/110 cum laude, graduation thesis with mention and admission to the "M. Ascoli" prize
- January, 2009 – July, 2010
Hematology Unit, AOUP "P. Giaccone" Palermo, University of Palermo
- Pre-graduate internship with specific participation in the clinical management of lymphoproliferative disorders

- Date (da – a) August, 2005
- Name and type of education or training institution Scholarship from the Ministry of Foreign Affairs at the University of Malta
- Main subjects/professional skills covered by the study English course
- Qualification awarded

MOTHER TONGUE
OTHER TONGUES

Italian

- Reading skills
- Writing skills
- Spoken proficiency

English

Very good
Very good
Good

French

Very good
Very good
Good

RELATIONAL SKILLS

Living and working with other people, in a multicultural environment, occupying positions where communication is important and in situations where teamwork is essential (e.g. culture and sport), etc.

Work activity characterized by maximum punctuality, assiduity and flexibility, with the ability to Make full use of the tools available. Excellent interaction skills at both level, individual and group with ample availability for team work. Strong ability to problem solving with determination and punctuality in achieving set objectives.

TECHNICAL SKILLS

With computers, specific kinds of equipment, machinery, etc.

Ability and experience in performing specific diagnostic-therapeutic invasive procedures including bone marrow aspirates and biopsies and lumbar punctures. Use of the main operating systems and browsers, office package, editing. Excellent knowledge and use of Mac OS operating systems.

DRIVING LICENSE

ITALIAN TYPE A.

SCIENTIFIC PUBLICATION

1. Carlisi M., Siragusa S., *Prevenzione del tromboembolismo venoso (TEV) nei pazienti con cancro*. Napoli, XXXIV CONGRESSO NAZIONALE SIAPAV, 21/24 Novembre 2012.
2. G. Caimi, M.Montana, C. Caracciolo, M. Carlisi, E. Hopps, I. Muratori, R. Lo Presti. *Aspetti emoreologici nella iperviscosità policitemica e sierica*. Catanzaro, VI CONGRESSO NAZIONALE DELLA SOCIETA' ITALIANA DI EMOREOLOGIA CLINICA E MCIROCICRCOLAZIONE, 26-26 Settembre 2015
3. Pagano L, Busca A et al. *Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations*. *Blood Rev.* 2016 Sep 17
4. Caimi G, Carlisi M, Urso C, Lo Presti R, Hopps E. *Clinical disorders responsible for plasma hyperviscosity and skin complications*. *Eur J Intern Med.* 2017 Apr 5.
5. Napolitano M, Santoro M, Mancuso S, Carlisi M, Raso S, Tarantino G, Accurso V, Siragusa S. *Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate*. *Clin Case Rep.* 2017 Aug 15;5(10):1573-1575.
6. Caimi G, Carlisi M, Montana M, Gallà E, Lo Presti R, Hopps E, Siragusa S. *Erythrocyte deformability and hemorheological profile in multiple myeloma*. *Clin Hemorheol Microcirc.* 2017 Oct.
7. Caimi G, Hopps E, Carlisi M, Montana M, Gallà E, Lo Presti R, Siragusa S. *Hemorheological parameters in Monoclonal Gammopathy of Undetermined Significance (MGUS)*. *Clin Hemorheol Microcirc.* 2017 Oct.
8. Mancuso S, Carlisi M, Sarocchi M, Napolitano M, Siragusa S. *Cardio-oncology in multiple myeloma: is it time for a specific focus?*. *Leuk Lymphoma.* 2017 Oct.
9. Mancuso S, Carlisi M, Napolitano M, Siragusa S. *Lymphomas and thyroid: Bridging the gap*. *Hematol Oncol.* 2018 Feb.
10. Mancuso S, Sucato G, Carlisi M, Santoro M, Tarantino G, Iannitto E, Napolitano M, Siragusa S. *Paroxysmal nocturnal hemoglobinuria: when delay in diagnosis and long therapy occur*. *Hematology Reports* 2018.
11. Caimi G, Carlisi M, Montana M, Gallà E, Hopps E, Lo Presti R, Siragusa S. *Red blood cell deformability in multiple myeloma*. *Clin Hemorheol Microcirc.* 2018 Apr.
12. Mancuso S, Sucato G, Carlisi M, Santoro M, Tarantino G, Iannitto E, Napolitano M, Siragusa S. *Paroxysmal nocturnal hemoglobinuria: When delay in diagnosis and long therapy occurs*. *Hematol Rep.* 2018 Mar 29;10(1):7523.
13. Mancuso S, Carlisi M, Santoro M, Napolitano M, Raso S, Siragusa S. *Immunosenescence and lymphomagenesis*. *Hematology Reports* 2018. *Immun Ageing.* 2018 Sep.
14. Conticello C, Romano A, Del Fabro V, Martino EA, Calafiore V, Sapienza G, Leotta V, Parisi MS, Markovic U, Garibaldi B, Leotta S, Cotzia E, Innao V, Mannina D, Neri S, Musso M, Scalone R, Cangialosi C, Acquaviva F, Cardinale G, Merenda A, Maugeri C, Uccello G, Poidomani M, Longo G, Carlisi M, Tibullo D, Di Raimondo F. *Feasibility, Tolerability and Efficacy of Carfilzomib in Combination with Lenalidomide and Dexamethasone in Relapsed Refractory Myeloma Patients: A Retrospective Real-Life Survey of the Sicilian Myeloma*

15. Santoro M, Accurso V, Mancuso S, Carlisi M, Raso S, Tarantino G, Di Piazza F, Perez A, Russo A, Siragusa S. Comparison between thrombotic risk scores in essential thrombocythemia and survival implications. *Hematol Oncol*. 2019 Aug 29.
16. Raimondo S, Urzi O, Conigliaro A, Lo Bosco G, Parisi S, Carlisi M, Siragusa S, Raimondi L, De Luca A, Giavaresi G, Alessandro R. Extracellular Vesicle microRNAs Contribute to the Osteogenic Inhibition of Mesenchymal Stem Cells in Multiple Myeloma. *Cancers*. 2020 Feb 14;12(2):449.
17. Accurso V, Santoro M, Mancuso S, Napolitano M, Carlisi M, Mattana M, Russo C, Di Stefano A, Sirocchi D, Siragusa S. The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep. *Insights Blood Disord*. 2020;13:2634853520978210.
18. Mancuso S, Carlisi M, Serra N, Napolitano M, Raso S, Consoli U, Palazzolo R, Lanza Cariccio MR, Siragusa S. Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study. *J Blood Med*. 2020 Aug 5;11:251-258.
19. Mancuso S, Carlisi M, Serra N, Sardo M, Bertuglia G, Pappalardo E, Siragusa S. The difference of free light chains as a predictor of kidney damage in patients with multiple myeloma. *Epidemiology Biostatistics and Public Health*. 2020;1:1 – 62020.
20. Carlisi M, Mancuso S, Caimi G, Siragusa S. Thrombotic risk in paroxysmal nocturnal hemoglobinuria-like (PNH-like) phenotype. *Clin Hemorheol Microcirc*. 2021;79(4):491-503.
21. Carlisi M, Mancuso S, Lo Presti R, La Manna MP, Orlando V, Siragusa S, Caimi G. Erythrocyte deformability in a group of monoclonal gammopathy of undetermined significance (Mgus) subjects. preliminary analysis. *Series on Biomechanics*. 2021;35:45-50.
22. Caimi G, Urso C, Brucculeri S, Amato C, Carlisi M, Lo presti R. An assessment of the hemorheological profile in patients with subclinical carotid atherosclerosis divided in relation to the number of cardiovascular risk factors and different degrees of insulin resistance. *Clinical Hemorheology and Microcirculation*. 2021;78:379-390.
23. Carlisi M, Mancuso S, Caimi G, Siragusa S. Paroxysmal nocturnal hemoglobinuria-like phenotype and thrombotic risk in several clinical disorders. *Panminerva Med*. 2021;63:232-233.
24. Caimi G, Lo Presti R, Carlisi M. Reflections on the unexpected laboratory finding of hemorheological alterations observed in some haematological disorders. *Microvascular Research*. 2021;136.
25. Carlisi M, Mancuso S, Lo Presti R, Siragusa S, Caimi G. Comparison between whole blood viscosity measured and calculated in subjects with monoclonal gammopathy of undetermined significance and in patients with multiple myeloma: Re-evaluation of our survey. *Clin Hemorheol Microcirc*. 2021;79(3):475-483.
26. Carlisi M, Mancuso S, Lo Presti R, Siragusa S, Caimi G. High Output Heart Failure in Multiple Myeloma: Pathogenetic Considerations. *Cancers (Basel)*. 2022 Jan 26;14(3):610.
27. Caimi G, Urso C, Brucculeri S, Amato C, Lo Presti R, Carlisi M. Uric acid and uric acid/creatinine ratio and their correlations with the hemorheological determinants in subjects with subclinical carotid atherosclerosis. *Clin Hemorheol Microcirc*. 2022 Jan 5. doi: 10.3233/CH-211322. Online ahead of print.
28. Mancuso S, Mattana M, Carlisi M, Santoro M, Siragusa S. Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy. *Int J Mol Sci*. 2022 Mar 21;23(6):3368.
29. Mancuso S, Mattana M, Santoro M, Carlisi M, Buscemi S, Siragusa S. Host-related factors and cancer: Malnutrition and non-Hodgkin lymphoma. *Hematol Oncol*. 2022 Aug;40(3):320-

30. Caimi G, Urso C, Brucculeri S, Amato C, Lo Presti R, Carlisi M. *Leukocyte subtypes, gelatinases, and their tissue inhibitors in a group of subjects with asymptomatic carotid atherosclerosis. Clin Hemorheol Microcirc.* 2022;82(1):37-51.
31. Botta C, Gigliotta E, Paiva B, Anselmo R, Santoro M, Otero PR, Carlisi M, Conticello C, Romano A, Solimando AG, Cerchione C, Vià MD, Bolli N, Correale P, Di Raimondo F, Gentile M, San Miguel J, Siragusa S. *Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant. Hematol Oncol.* 2022 Dec;40(5):987-998. doi: 10.1002/hon.3041.
32. Caimi G, Presti RL, Mancuso S, Siragusa S, Carlisi M. *Erythrocyte deformability profile evaluated by laser diffractometry in patients with multiple myeloma: Re-examination of our cases. Microvasc Res.* 2023 Mar;146:104473. doi: 10.1016/j.mvr.2022.104473.
33. Plano F, Corsale AM, Gigliotta E, Camarda G, Vullo C, Di Simone M, Shekarkar Azgomi M, Speciale M, Carlisi M, Caccamo N, Dieli F, Meraviglia S, Siragusa S, Botta C. *Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again. Hematol Rep.* 2023 Jan 9;15(1):23-49. doi: 10.3390/hematolrep15010004.
34. Carlisi M, Lo Presti R, Mancuso S, Siragusa S, Caimi G. *Calculated Whole Blood Viscosity and Albumin/Fibrinogen Ratio in Patients with a New Diagnosis of Multiple Myeloma: Relationships with Some Prognostic Predictors. Biomedicines.* 2023 Mar 21;11(3):964. doi: 10.3390/biomedicines11030964.
35. Caimi G, Carlisi M. *The unpredictable erythrocyte deformability alteration in some hematological disorders: How the classification of primary hyperviscosity syndromes could change. Clin Hemorheol Microcirc.* 2023;83(4):341-349.
36. Caimi G, Lo Presti R, Corrado E, Montana M, Carlisi M. *Red Cell Distribution Width and Elongation Index in a Cohort of Patients With Juvenile Acute Myocardial Infarction. Clin Appl Thromb Hemost.* 2023 Jan-Dec;29:10760296231186148. doi: 10.1177/10760296231186148.
37. Caimi G, Lo Presti R, Carollo C, Montana M, Carlisi M. *Polymorphonuclear phenotypical expression of CD18, at baseline and after in vitro activation, in several clinical disorders: Revision of our case series. Clin Hemorheol Microcirc.* 2023;85(1):41-58. doi: 10.3233/CH-231771.
38. Carlisi M, Presti RL, Mancuso S, Siragusa S, Caimi G. *Thrombotic Risk and Calculated Whole Blood Viscosity in a Cohort of Patients With New Diagnosis of Multiple Myeloma. Clin Appl Thromb Hemost.* 2024 Jan-Dec;30:10760296231222477. doi: 10.1177/10760296231222477.
39. Caimi G, Carlisi M, Presti RL. *Red Blood Cell Distribution Width, Erythrocyte Indices, and Elongation Index at Baseline in a Group of Trained Subjects. J Clin Med.* 2023 Dec 27;13(1):151. doi: 10.3390/jcm13010151.
40. Carlisi M, Presti RL, Plano F, Mancuso S, Siragusa S, Caimi G. *Changes in RDW according to prognostic predictors in newly diagnosed multiple myeloma. Sci Rep.* 2024 Feb 3;14(1):2832. doi: 10.1038/s41598-024-53385-6.
41. Mancuso S, Mattana M, Giammancheri F, Russello F, Carlisi M, Santoro M, Siragusa S. *Bone damage and health-related quality of life in Hodgkin lymphoma survivors: closing the gaps. Front Oncol.* 2024 Feb 9;14:1201595. doi: 10.3389/fonc.2024.1201595.
42. Caimi G, Lo Presti R, Urso C, Brucculeri S, Carlisi M. *Neutrophil/HDL-C, Lymphocyte/HDL-C and Monocyte/HDL-C in subjects with asymptomatic carotid atherosclerosis. Clin Hemorheol Microcirc.* 2024 May 16. doi: 10.3233/CH-232019.
43. Caimi G, Urso C, Brucculeri S, Lo Presti R, Carlisi M. *Calculated whole blood viscosity in non-diabetic subjects with asymptomatic carotid atherosclerosis: How insulin resistance may affect blood viscosity. Clin Hemorheol Microcirc.* 2024;88(2):199-209. doi: 10.3233/CH-

44. De Novellis D, Derudas D, Vincelli D, Fontana R, Della Pepa R, Palmieri S, Accardi F, Rotondo F, Morelli E, Gigliotta E, Roccotelli D, Marano L, Barone ML, Cetani G, Esposito D, Lazzaro A, Delle Cave G, Serio B, Morini D, Porrazzo M, Urciuoli E, Masucci C, Fanelli F, Rizzo M, Arcamone M, Trastulli F, Rocco S, Leone A, Bianco R, Salvatore F, Idato A, Sicari M, Tosi P, Rascato MG, Di Perna M, Falcone AP, Morello L, Carlisi M, Svanera G, Annunziata M, Frigeri F, Califano C, Carella AM, Marcacci G, Pane F, Risitano AM, Giudice V, Botta C, Selleri C. *Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients*. *Eur J Haematol*. 2025 Jan;114(1):105-114. doi: 10.1111/ejh.14314.
45. Carlisi M, Lo Presti R, Spoto C, Mancuso S, Siragusa S, Caimi G. *Calculated haemorheological profile and laboratory parameters in new diagnosed multiple myeloma patients: retrospective analysis according to survival*. *Ther Adv Hematol*. 2024 Nov 23;15:20406207241298865. doi: 10.1177/20406207241298865.
46. Carlisi M, Presti RL, Pirrera A, Augello AE, Siragusa S, Caimi G. *Prognostic potential of albumin to fibrinogen ratio in multiple myeloma patients*. *Ann Hematol*. 2025 Oct 20. doi: 10.1007/s00277-025-06630-5.
47. Gay F, Buda G, Petrucci MT, Bolli N, Cea M, Derudas D, Mangiacavalli S, Montefusco V, Antonioli E, Barilà G, Basso M, Bertazzoni P, Bertuglia G, Bianco R, Carlisi M, Giudice MLD, Della Pepa R, Fazio F, Franceschini L, Furlan A, Gozzetti A, Liberatore C, Mancuso K, Martino EA, Mele G, Monaco F, Morè S, Paris L, Pavan L, Pezzatti S, Rago A, Ribolla R, Roncato R, Rossini B, Sgherza N, Vassallo F, Vincelli DI, Za T, Musto P, Zamagni E. *Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape*. *ESMO Open*. 2026 Mar;11(3):106054. doi: 10.1016/j.esmoop.2025.106054.
48. Caimi G, Lo Presti R, Urso C, Brucculeri S, Amato C, Carlisi M. *Asymptomatic carotid atherosclerosis: Oxidative stress, clinical and inflammation parameters and blood viscosity according to the hemoglobin level*. *Clin Hemorheol Microcirc*. 2026 Jan;92(1-2):17-24. doi: 10.1177/13860291261433162.
49. Carlisi M, Lo Presti R, Indelicato S, Siragusa S, Caimi G. *Estimated Whole Blood Viscosity in Smoldering Multiple Myeloma: Preliminary Data from a Retrospective Single Center Analysis*. *J Blood Med*. 2026 Jul 14;17:599779. doi: 10.2147/JBM.S599779.

ADDITIONAL INFORMATION

Current Membership of the Following Scientific Societies:

- Italian Society of Hematology (SIE)
- Italian Society of Clinic Hemorheology and Microcirculation (SIECM).
- Member of directive council SIECM 2022-2026
- Member of editorial board of Clinical Hemorheology and Microcirculation Journal

Reviewer for the following journals:

- Archives of Hematology Case Reports and Reviews
- Journal of Clinical Medicine
- Current Oncology
- Leukemia & Lymphoma
- Scientific Reports
- Thrombosis Journal
- Frontiers in Physiology
- Therapeutic Advances in Hematology

INVITED SPEECHES

1. Approach to the hematological patient. Title: "Detection of lymphadenopathy and/or splenomegaly". Marsala (TP), December 10, 2016.
2. V CONGRESS "EMOREOLOGY AND MICROCIRCULATION FROM THE LABORATORY TO THE CLINIC" organized by the Istituto Superiore di Sanità. Title: "Hemorheological profile in subjects affected by Monoclonal Gammopathy of Undetermined Significance (MGUS)". Rome, Istituto Superiore di Sanità, January 27, 2017.
3. Acoi Regional Congress. Abdominal traumatology - Operative and Non-Operative Management of solid organ injuries. Title: "Operational treatment - Current affairs on LMWH". Alcamo, 10 March 2017.
4. 3rd advanced training course in hemostasis and thrombosis. Title: "Congenital and acquired hemorrhagic diseases - Morphological workshop". Palermo, April 07, 2017.
5. 3rd advanced training course in hemostasis and thrombosis. Title: "Thrombophilia and clinical manifestations - Antiphospholipid antibody syndrome". Palermo, April 08, 2017.
6. 3rd advanced training course in hemostasis and thrombosis. Title: "Thrombophilia and clinical manifestations - Heparin-induced thrombocytopenia". Palermo, April 08, 2017.
7. 3rd REGIONAL MEETING OF THE SICILIAN RSAs CHRONICITY AND RESIDENTIALITY. Report title: "VTE prophylaxis in cancer patients". Bagheria (PA), May 12, 2017.
8. Thrombotic microangiopathies (TMA) in the Sicilian regional context: from differential diagnosis to patient management. Title: "Thrombotic microangiopathies - Role of ADAMTS13". Catania, June 09, 2017.
9. Multiple myeloma therapy - Opinion leaders compared. Title: "Prophylaxis of thromboembolic events in multiple myeloma". Grottaferrata (RO), July 07, 2017.
10. VII NATIONAL CONGRESS - Italian Society of Clinical Hemorheology and Microcirculation. Title: "Hemorheological structure in multiple myeloma and monoclonal gammopathy of uncertain significance". Verona, September 22, 2017.
11. 4th Advanced training course in hemostasis and thrombosis. Title: "Morphological workshop". Palermo, April 13, 2018.
12. I Neoplastic hematology workshops. Title: "Plasma cell leukemia". Palermo, January 25, 2019.
13. 5th Advanced training course in hemostasis and thrombosis. Title: "Morphological workshop". Palermo, April 11, 2019.
14. Taormina Multiple Myeloma Workshop Guidelines. Title: "How I treat the elderly patient". Taormina, May 18, 2019.
15. VIII CONGRESS OF THE ITALIAN SOCIETY OF CLINICAL HAEMOREOLOGY AND MICROCIRCULATION. Title: "Thrombophilic diathesis PNH like". Modena, September 20, 2019.
16. MULTIPLE MYELOMA DISCUSSION VIRTUAL MEETING. MRD: clinical importance and impact of treatments. November 05, 2020.
17. I SOHO ITALY- CLINICAL AND BIOLOGICAL SCHOOL OF MULTIPLE MYELOMA- Functional role of Bone Marrow CD8+ Tissue-Resident Memory T-Cells in Multiple Myeloma. December 16, 2020.
18. 7th HIGH TRAINING COURSE IN HEMOSTASIS AND THROMBOSIS - Morphological workshop - Morphological alterations during SARS-COV2 infection.

19. HEMATOLOGY OF THE THIRD MILLENNIUM. NETWORKING AND MULTIDISCIPLINARY APPROACH. Frontline treatment of multiple myeloma and RR. October 01, 2020.
20. CONVEGNO REGIONALESIE 2024 DELEGAZIONE SICILIA. Title: Relapsed/Refractory Multiple Myeloma. Palermo, March 22, 2024.
21. X SIECM NATIONAL CONGRESS - FROM DYSFUNCTION MICROCIRCULATORY TO ORGAN DAMAGE. Title: "Calculated whole blood viscosity and albumin/fibrinogen ratio in patients with new diagnosis of multiple myeloma: role of some prognostic predictors". Padua, June 07, 2024.
22. X SIECM NATIONAL CONGRESS - FROM DYSFUNCTION MICROCIRCULATORY TO ORGAN DAMAGE. Title: "Hemorheological profile in multiple myeloma". Padua, June 08, 2024.
23. CURRENT EVENTS AND PROSPECTS IN HEMATOLOGY 2025 - Title: "Relapse Treatment: Bispecific". Palermo, September 25, 2025.
24. NEXT GENERATION IN MULTIPLE MYELOMA - Title: "Management of adverse events with Selinexor". Palermo, November 10, 2025.
25. MYELO NEXT- REFLECTING ON NEXT CLINICAL SCENARIOS ENCOUNTERED IN MULTIPLE MYELOMA CARE - Title: "Optimization of available therapies in real life for the treatment of relapsed refractory MM – balancing hematological response and dose intensity through dose optimization". Rome, February 10, 2026.

AUTOCERTIFICAZIONE RESA AI SENSI DELLE LEGGI 15/68, 127/97 E 445/2000

La sottoscritta altresì autorizza al trattamento dei dati personali ai sensi e per effetto del D.L. 196/2003 e dichiara sotto la propria responsabilità che la documentazione dichiarata e/o allegata è conforme agli originali, presentabili qualora fossero richiesti.

La sottoscritta inoltre è consapevole che, in caso di falsità o dichiarazioni mendaci, incorre nelle sanzioni penali di cui all'art. 76 D.P.R. 445/2000, oltre alla decadenza dai benefici conseguiti grazie al provvedimento emanato in base alle dichiarazioni non veritiere di cui al precedente art. 75.

Palermo September 05, 2026

